News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Piramal Life Sciences Acquires Assets of Canadian Medtech Firm BioSyntech for Can $3.9 Million
June 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SCRIP -- Piramal Healthcare has signed an agreement to acquire the assets of the Canadian medical technology firm, BioSyntech, for a consideration of Can$3.9 million.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
MORE ON THIS TOPIC
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
·
2 min read
·
Gabrielle Masson
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
·
1 min read
·
Tristan Manalac
Venture capital
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
September 23, 2026
·
1 min read
·
Annalee Armstrong
autoimmune disease
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study
September 23, 2026
·
2 min read
·
Tristan Manalac
